CARsgen Therapeutics
Shanghai · Founded 2014
About CARsgen Therapeutics
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Company Facts
- Founded: 2014
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Total funding: $276.0M
- Funding stage: IPO
- Last round: Series C (Nov 2020)
- Ticker: hkg:2171
- Website: http://www.carsgen.com
- Phone: +862154489928
Industries & Categories
Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/carsgen-therapeutics-22152 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.